The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
Open accessAbstract
Background: Polycomb repressive complex 2 (PRC2) mediates gene silencing through histone H3K27 methylation. PRC2 components are over-expressed in metastatic prostate cancer (PC), and are required for cancer stem cell (CSC) self-renewal. 3-Dezaneplanocin-A (DZNeP) is an inhibitor of PRC2 with broad anticancer activity. Method: we investigated the effects of DZNeP on cell proliferation, tumorigenicity and invasive potential of PC cell lines (LNCaP and DU145). Results: Exploring GEO and Oncomine databases, we found that specific PRC2 genes (EED, EZH2, SUZ12) predict poor prognosis in PC. Non-toxic DZNeP concentrations completely eradicated LNCaP and DU145 prostatosphere formation, and significantly reduced the expression of CSC markers. At comparable doses, other epigenetic drugs were not able to eradicate CSCs. DZNeP was also able to reduce PC cell invasion. Cells pre-treated with DZNeP were significantly less tumorigenic (LNCaP) and formed smaller tumors (DU145) in immunocompromised mice. Conclusion: DZNeP is effective both in vitro and in vivo against PC cells. DZNeP antitumor activity is in part mediated by inhibition of CSC tumorigenic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q. (2007) · Genes & Development · doi:10.1101/gad.1524107 · Cited by 895 · cited 5×
“More recently, this compound showed a broad anticancer activity, with little or no effects on non-transformed cells [19].”
BackgroundResultInfluentialLenferink, A. E. G., Cantin, C., Nantel, A., Wang, E., Durocher, Y., Banville, M., Paul-Roc, B., Marcil, A., Wilson, M. R., & O'Connor-McCourt, M. D. (2010) · Oncogene · doi:10.1038/onc.2009.399 · Cited by 81
Cited by
Tiwari, N., Tiwari, V. K., Waldmeier, L., Balwierz, P. J., Arnold, P., Pachkov, M., Meyer-Schaller, N., Schübeler, D., van Nimwegen, E., & Christofori, G. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.020 · Cited by 484
Epigenetics in cancer stem cells
Toh, T. B., Lim, J. J., & Chow, E. K.-H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0596-9 · Cited by 422
Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting
Eun, K., Ham, S. W., & Kim, H. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.3.222 · Cited by 382
The role of EZH2 in tumour progression
Chang, C.-J., & Hung, M.-C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.551 · Cited by 332
Regulation and Role of EZH2 in Cancer
Yamaguchi, H., & Hung, M.-C. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.46.3.209 · Cited by 287
Metadata
- Authors
- Crea, F., Hurt, E. M., Mathews, L. A., Cabarcas, S. M., Sun, L., Marquez, V. E., Danesi, R., & Farrar, W. L.
- Venue
- Molecular Cancer
- Published
- 2011-04-18
- Volume
- 10
- Issue
- 1
- Pages
- 40-40
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2100046750
- Cited by
- 173
- References
- 3
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. https://app.cochat.ai/papers/10.1186/1476-4598-10-40
- The paper
- Crea, F., Hurt, E. M., Mathews, L. A., Cabarcas, S. M., Sun, L., Marquez, V. E., Danesi, R., & Farrar, W. L. (2011). Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Molecular Cancer. https://doi.org/10.1186/1476-4598-10-40
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.